TEL AVIV, Israel, Nov. 07, 2017 /PRNewswire/ --
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), a clinical-stage
biopharmaceutical company focused on the development of a
once-daily, oral therapy for the treatment of nonalcoholic
steatohepatitis, or NASH and other liver diseases, today announced
that its senior management will provide an overview of the
scientific rationale and ongoing clinical development program of
Aramchol™, a novel, once-daily, oral therapy for the treatment of
NASH at the Stifel 2017 Healthcare Conference, being held at the
Lotte New York Palace Hotel in New York
City.
Galmed Pharmaceuticals Presentation Details:
Date: Wednesday, November 15
Time: 10:15 am Eastern Time
Location: Garrison room, 5th Floor
About Aramchol™ and Non-alcoholic Steatohepatitis
(NASH)
Aramchol™ (arachidyl amido cholanoic acid) is a novel fatty acid
bile acid conjugate, inducing beneficial modulation of
intra-hepatic lipid metabolism. Aramchol™'s ability to modulate
hepatic lipid metabolism was discovered and validated in animal
models, demonstrating down regulation of the three key pathologies
of NASH: steatosis, inflammation and fibrosis. The effect of
Aramchol™ on fibrosis is mediated by down regulation of steatosis
and directly on human collagen producing cells. Aramchol™ has been
granted Fast Track designation status by the FDA for the treatment
of NASH.
NASH is an emerging world crisis impacting an estimated 3%
to 5% of the U.S. population and an estimated 2% to 4% globally. It
is the fastest growing cause of liver cancer and liver transplant
in the U.S. due to the rise in obesity. NASH is the progressive
form of non-alcoholic fatty liver disease that can lead to
cardiovascular disease, cirrhosis and liver-related mortality.
About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on
the development of Aramchol™, a first in class, novel, once-daily,
oral therapy for the treatment of NASH for variable populations, as
well as other liver associated disorders. Galmed is currently
conducting the ARREST Study, a multicenter, randomized, double
blind, placebo-controlled Phase IIb clinical study designed to
evaluate the efficacy and safety of Aramchol™ in subjects with
NASH, who are overweight or obese, and who are pre-diabetic or
type-II-diabetic. Galmed also sponsors the ARRIVE Study, a
proof-of-concept Phase IIa clinical trial designed to evaluate the
safety and efficacy of Aramchol™ in up to 50 patients with
HIV-associated NAFLD and lipodystrophy. The ARRIVE Study is an
investigator-initiated trial, conducted at the University of California, San Diego by Professor
Rohit Loomba. More information about
the ARREST Study and the ARRIVE Study may be found on
ClinicalTrials.gov identifiers: NCT02279524 and NCT02684591,
respectively.
View original
content:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-provide-corporate-overview-at-the-stifel-2017-healthcare-conference-300550793.html
SOURCE Galmed Pharmaceuticals Ltd.